KOR

e-Article

Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network‐RIKEN (PGRN‐RIKEN) Collaboration
Document Type
article
Source
Clinical Pharmacology & Therapeutics. 100(5)
Subject
Pharmacology and Pharmaceutical Sciences
Biomedical and Clinical Sciences
Genetics
Human Genome
Patient Safety
Good Health and Well Being
Genome-Wide Association Study
Humans
Intersectoral Collaboration
Pharmacogenetics
Pharmacology & Pharmacy
Pharmacology and pharmaceutical sciences
Language
Abstract
Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN-RIKEN, with the goal of accelerating GWAS of drug response phenotypes.